Compare ARKR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKR | MDXH |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 21.1M |
| IPO Year | 1994 | 2021 |
| Metric | ARKR | MDXH |
|---|---|---|
| Price | $5.76 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 2.2K | ★ 786.3K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $165,751,000.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $0.40 |
| 52 Week High | $9.50 | $5.33 |
| Indicator | ARKR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 30.82 |
| Support Level | $5.64 | N/A |
| Resistance Level | $7.04 | $3.79 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 42.86 | 13.00 |
Ark Restaurants Corp owns and operates around 17 restaurants and bars, 16 fast food concepts, and catering operations in the USA. The Las Vegas operations include New York Hotel & Casino Resort, hotel room service operations, banquet facilities, employee dining room, food court concepts, and a restaurant within the Planet Hollywood Resort and Casino. It operates a restaurant and a bar in the Resorts Atlantic City Hotel and Casino and a restaurant in the Tropicana Hotel and Casino. The Florida operations include The Rustic Inn in Dania Beach, Shuckers in Jensen Beach, JB's on the Beach in Deerfield Beach, The Blue Moon Fish Company in Fort Lauderdale, and fast food facilities in Tampa and Hollywood. In Alabama, it operates Original Oyster Houses in Gulf Shores and Spanish Fort.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.